Psoriasis induced by topical imiquimod

We report the provocation of localized psoriasis at the sites of application of topical imiquimod, possibly evolving into a generalized flare. A patient with pre‐existing psoriasis that had been stable for 14 years was treated with imiquimod 5% cream daily for 6 weeks to three superficial basal cell carcinomas. During treatment one of the lesions developed severe local skin reactions necessitating rest periods, and received only 18 applications in 6 weeks. The other two lesions were treated for all 42 days. Psoriasiform changes developed at all three application sites. Nine‐and‐a‐half weeks after completing treatment the patient developed disseminated small psoriatic lesions. Other recognized triggers of psoriasis were not identified. The psoriasis resolved slowly with conventional treatment.

[1]  S. Akira,et al.  Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway , 2002, Nature Immunology.

[2]  R. Marks,et al.  Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. , 2001, Journal of the American Academy of Dermatology.

[3]  S. Kossard,et al.  Imiquimod 5% cream in the treatment of Bowen's disease. , 2001, Journal of the American Academy of Dermatology.

[4]  A. Downs,et al.  Exacerbation of psoriasis by interferon‐alpha therapy for hepatitis C , 2000, Clinical and experimental dermatology.

[5]  M. Wiselka,et al.  Extensive psoriasis induced by interferon alfa treatment for chronic hepatitis C , 2000, Postgraduate medical journal.

[6]  K. Beutner,et al.  Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. , 1999, Journal of the American Academy of Dermatology.

[7]  E. Berg,et al.  IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. , 1999, Journal of immunology.

[8]  N. Yawalkar,et al.  Expression of interleukin-12 is increased in psoriatic skin. , 1998, The Journal of investigative dermatology.

[9]  Smith,et al.  Percutaneous penetration of Aldara cream, 5% during the topical treatment of genital and perianal warts. , 1998, Primary care update for Ob/Gyns.

[10]  M. Gore,et al.  A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily. , 1996, British Journal of Cancer.

[11]  T. Testerman,et al.  Cytokine induction by the immunomodulators imiquimod and S‐27609 , 1995, Journal of leukocyte biology.

[12]  S. Lessin,et al.  De novo development of psoriatic plaques in patients receiving interferon alfa for treatment of erythrodermic cutaneous T-cell lymphoma. , 1995, Journal of the American Academy of Dermatology.

[13]  G. Pozzato,et al.  Psoriasis exacerbation induced by interferon-alpha. Report of two cases. , 1993, Acta dermato-venereologica.

[14]  E. Schrumpf,et al.  Psoriasis induced by interferon‐α , 1991 .

[15]  G. Rassner,et al.  Psoriasis induced at the injection site of recombinant interferon gamma. Results of immunohistologic investigations. , 1990, Archives of dermatology.

[16]  T. Shiohara,et al.  Psoriasis occurring predominantly on warts. Possible involvement of interferon alfa. , 1988, Archives of dermatology.

[17]  M. Gumbs,et al.  Extensive psoriasis induced by interferon alfa treatment for chronic hepatitis , 2000 .

[18]  G. Pasero,et al.  Psoriatic arthritis with spinal involvement in a patient receiving alpha-interferon for chronic hepatitis C. , 1997, Scandinavian journal of rheumatology.

[19]  P. Martín,et al.  Exacerbation of psoriasis due to interferon-α treatment of chronic active hepatitis , 1993 .

[20]  G. Webster,et al.  Exacerbation of psoriasis due to interferon-alpha treatment of chronic active hepatitis. , 1993, The American journal of gastroenterology.

[21]  E. Schrumpf,et al.  Psoriasis induced by interferon-alpha. , 1991, The British journal of dermatology.